Loading
Life sciences · Journal article
Nature Communications · August 11, 2026
Encouraging direction, but not yet definitive.
This preclinical study identifies a metabolic pathway by which adipocyte-derived β-hydroxybutyrate promotes multiple myeloma cell survival under glucose deprivation, mediated by OXCT1-dependent ketolysis and NAT10-dependent IRF4 acetylation. Genetic ablation and pharmacologic inhibition of this pathway, combined with metformin, showed synergistic anti-tumor activity in vivo, suggesting a potential therapeutic strategy that requires clinical translation.
Preclinical mechanistic study with genetic and pharmacologic manipulation and in vivo xenograft validation. Multiple myeloma cell lines and primary adipocytes under glucose deprivation; in vivo studies in an unspecified xenograft or syngeneic model. Intervention: Glucose restriction; genetic ablation of Hmgcs2 in adipocytes; pharmacologic inhibition of AMPK (metformin), OXCT1 (pimozide), and NAT10 (remodelin), alone and in combination. Compared with: Standard culture conditions (presumed adequate glucose); wild-type adipocytes; single-agent drug treatments.
Glucose restriction activates AMPK in MM cells, disrupting HSP90-IRF4 binding and promoting IRF4 degradation The same glucose stress stimulates adipocytes to produce β-hydroxybutyrate MM cells utilize β-OHB through OXCT1-mediated ketolysis, fueling NAT10-dependent acetylation of IRF4 at K87 to restore IRF4-HSP90 binding
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work identifies a targetable metabolic pathway linking obesity to MM progression and proposes a rational drug combination (AMPK activator plus OXCT1 or NAT10 inhibitor) warranting clinical investigation. The findings underscore the importance of metabolic crosstalk in the tumor microenvironment but remain preclinical; patient benefit is unproven.
Mechanistic discovery with in vivo validation of a synergistic drug combination in a preclinical model, but lacks clinical trial data and human patient outcomes.
As stated by the source record.
Quoted from the source exactly as published.
This work identifies a targetable metabolic pathway linking obesity to MM progression and proposes a rational drug combination (AMPK activator plus OXCT1 or NAT10 inhibitor) warranting clinical investigation. The findings underscore the importance of metabolic crosstalk in the tumor microenvironment but remain preclinical; patient benefit is unproven.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Multiple myeloma (MM) remains an incurable blood cancer. Obesity is a known risk factor, but how adipocytes promote MM progression is not fully understood. Here, we uncover a metabolic crosstalk between adipocytes and MM cells that promotes MM cell survival under glucose deprivation. We show that glucose restriction activates AMPK, disrupting HSP90-IRF4 binding and rendering IRF4 susceptible to TRIM21-mediated proteasomal degradation. Paradoxically, the same stress stimulates adipocytes to produce β-hydroxybutyrate (β-OHB). MM cells utilize β-OHB through OXCT1-mediated ketolysis, fueling NAT10-dependent acetylation of IRF4 at K87, which restores IRF4-HSP90 binding and sustains tumor cell survival. Genetic ablation of the rate-limiting ketogenic enzyme Hmgcs2 in adipocytes abrogates this protective effect. Importantly, combining an AMPK activator (metformin) with an OXCT1 inhibitor (pimozide) or a NAT10 inhibitor (remodelin) shows synergistic anti-tumor activity in vivo. Our findings position adipocyte-derived β-OHB as a critical metabolic adaptor and highlight a potential combination therapy for MM. Multiple cell populations within the bone tumour microenvironment have been shown to support multiple myeloma (MM). Here, the authors show that under glucose deprived conditions, adipocytes produce β-hydroxybutyrate, which promotes MM cell survival.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.